Previous 10 | Next 10 |
2023-11-14 22:54:09 ET Lucid Diagnostics Inc. (LUCD) Q3 2023 Results Conference Call November 14, 2023 08:30 AM ET Company Participants Michael Parks - VP, IR Dr. Lishan Aklog - Chairman, CEO Dennis McGrath - EVP, CFO Conference Call Participants Kyle...
PAVmed Provides Business Update and Third Quarter Financial Results PR Newswire Lucid's quarterly revenue increased 392 percent sequentially Veris Health commercial expansion efforts underway, with next-generation Veris Cancer Care Platform launching in Q4 Conf...
2023-11-14 01:06:21 ET More on Lucid Diagnostics Seeking Alpha’s Quant Rating on Lucid Diagnostics Historical earnings data for Lucid Diagnostics Financial information for Lucid Diagnostics For further details see: Lucid Diagnostics Non-GAAP EPS of...
Lucid Diagnostics Provides Business Update and Third Quarter Financial Results PR Newswire Quarterly EsoGuard ® test volume and revenue increased 17 percent and 392 percent sequentially, respectively Conference call and webcast to be held tomorrow, November ...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
Lucid Diagnostics Inc. (LUCD) is expected to report for Q3 2023
Lucid Diagnostics Launches Next-Generation EsoGuard® Esophageal DNA Test and Announces Upcoming Investor Day PR Newswire EsoGuard 2.0 incorporates advanced molecular techniques and leverages improvements in sample DNA yields and processes to enhance assay performance and ...
Lucid Diagnostics to Present at Canaccord Genuity Medtech, Diagnostics, and Digital Health & Services Forum Lucid Diagnostics to Present at Canaccord Genuity Medtech, Diagnostics, and Digital Health & Services Forum PR Newswire Lishan Aklog , M.D., Chairman &am...
PAVmed to Hold a Business Update Conference Call and Webcast on November 15, 2023 PR Newswire Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK , Nov. 1, 2023 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) ("PAVmed" or the "...
Lucid Diagnostics Announces PREVENT and PREVENT-FF Registries of EsoGuard® Esophageal Precancer Detection PR Newswire Clinical registries are collecting real-world clinical utility and clinical validity data on EsoGuard testing in general at-risk populations and fire...
News, Short Squeeze, Breakout and More Instantly...
Lucid Diagnostics Inc. Company Name:
LUCD Stock Symbol:
NASDAQ Market:
Lucid Diagnostics Inc. Website:
Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume PR Newswire Quarterly EsoGuard ® test volume increased 31 percent sequentially NEW YORK , July 23, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("L...
Lucid Diagnostics Launches New Corporate Website PR Newswire NEW YORK , July 11, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and majority-ow...
Lucid Diagnostics Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population PR Newswire Prospective screening study demonstrates excellent EsoGuard s...